It is a link to move in the page.
To global navigation
To the text
To local navigation
To site information
Font Size
Language
news release
March 9, 2010
TMX-67 (ADENURIC®) Launches in Europe Novel Drug for Chronic Management of Hyperuricemia in Gout Patients
December 25, 2009
Teijin Pharma Submits New Drug Application for TMX-67, Chronic Management of Hyperuricemia in Patients with Gout in Japan
Archives
corporate profile
Message from the President
Corporate Profile
Overview of Core Business
Global Operations
Compliance
Organization
Corporate Social Responsibility(CSR)
Synergies of the Teijin Group
Research and Development
Customer and marketing support services
History
Office Locations
